GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (FRA:7RG0) » Definitions » Cyclically Adjusted Price-to-FCF

Regulus Therapeutics (FRA:7RG0) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Regulus Therapeutics Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regulus Therapeutics Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Regulus Therapeutics's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Cyclically Adjusted Price-to-FCF Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regulus Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regulus Therapeutics's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Regulus Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regulus Therapeutics's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Cyclically Adjusted Price-to-FCF falls into.



Regulus Therapeutics Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Regulus Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Regulus Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.287/131.7762*131.7762
=-0.287

Current CPI (Mar. 2024) = 131.7762.

Regulus Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -21.137 100.560 -27.699
201409 -19.110 100.428 -25.075
201412 -24.258 99.070 -32.266
201503 -25.472 99.621 -33.694
201506 -20.810 100.684 -27.236
201509 -25.277 100.392 -33.179
201512 -36.890 99.792 -48.713
201603 -19.098 100.470 -25.049
201606 -34.870 101.688 -45.188
201609 -32.386 101.861 -41.897
201612 -32.844 101.863 -42.489
201703 -39.844 102.862 -51.044
201706 -34.781 103.349 -44.348
201709 -13.136 104.136 -16.623
201712 -10.878 104.011 -13.782
201803 -14.594 105.290 -18.265
201806 -12.026 106.317 -14.906
201809 -11.274 106.507 -13.949
201812 -4.008 105.998 -4.983
201903 -3.779 107.251 -4.643
201906 -3.014 108.070 -3.675
201909 -2.056 108.329 -2.501
201912 -2.134 108.420 -2.594
202003 -2.258 108.902 -2.732
202006 -1.557 108.767 -1.886
202009 -1.001 109.815 -1.201
202012 0.548 109.897 0.657
202103 -0.679 111.754 -0.801
202106 -0.554 114.631 -0.637
202109 -0.546 115.734 -0.622
202112 -0.650 117.630 -0.728
202203 -0.403 121.301 -0.438
202206 -0.411 125.017 -0.433
202209 -0.454 125.227 -0.478
202212 -0.354 125.222 -0.373
202303 -0.450 127.348 -0.466
202306 -0.302 128.729 -0.309
202309 -0.325 129.860 -0.330
202312 -0.281 129.419 -0.286
202403 -0.287 131.776 -0.287

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regulus Therapeutics  (FRA:7RG0) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Regulus Therapeutics Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics (FRA:7RG0) Business Description

Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

Regulus Therapeutics (FRA:7RG0) Headlines

No Headlines